How India Exports Bleomycin to the World

In the United States, Bleomycin has been approved by the FDA for various oncological indications. The original New Drug Application (NDA) for Bleomycin sulfate (Blenoxane) was approved on February 20, 1996, for the treatment of malignant pleural effusion, with exclusivity ending on February 20, 2003. Additionally, Bleomycin received orphan drug designation on September 17, 1993, for the treatment of malignant pleural effusion. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Bleomycin sulfate, indicating the presence of generic competition. Notably, the ANDA for Bleomycin sulfate by Pharmacia was approved on June 3, 1996. The substantial number of active Indian exporters (206) underscores the competitive landscape and the importance of adhering to stringent FDA regulations to ensure market access.

In the European Union, Bleomycin has been subject to regulatory scrutiny. A notable instance occurred in March 2009 when the European Medicines Agency (EMA) completed a referral procedure concerning Bleomycin powder for solution for injection (15 U/vial) from Pharmachemie BV. The Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits outweighed the risks, leading to the granting of marketing authorization across EU Member States. (ema.europa.eu) This decision highlights the importance of harmonized regulatory assessments within the EU. Manufacturers exporting to the EU and UK must comply with Good Manufacturing Practice (GMP) requirements as stipulated by the EMA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). These standards ensure product quality and safety, necessitating rigorous adherence by Indian exporters to maintain market access.

Bleomycin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in cancer treatment. This inclusion facilitates its adoption in national formularies worldwide. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is imperative for manufacturers to ensure global acceptance and maintain product quality.

In India, Bleomycin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, Bleomycin is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the export of critical pharmaceuticals.

The primary patents for Bleomycin have expired, leading to the availability of generic versions in various markets. This expiration has intensified competition among manufacturers, including the 206 active Indian exporters, and has contributed to the widespread accessibility of Bleomycin for cancer treatment globally.

In January 2023, the European Medicines Agency (EMA) conducted a Periodic Safety Update Report Single Assessment (PSUSA) for Bleomycin, resulting in a variation to the product information to enhance safety monitoring. (ema.europa.eu) In March 2025, the EMA issued a reminder regarding the contraindication of using Adcetris (brentuximab vedotin) in combination with Bleomycin due to increased pulmonary toxicity risks. (ema.europa.eu) These developments underscore the importance of continuous pharmacovigilance and adherence to updated regulatory guidelines to ensure patient safety and compliance in the pharmaceutical industry.

Bleomycin, an antineoplastic agent, is primarily produced in India. However, the Indian pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and intermediates essential for Active Pharmaceutical Ingredient (API) synthesis. According to the U.S. Pharmacopeia's Medicine Supply Map, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, while 16% come exclusively from India. This dependency exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or environmental regulations affecting Chinese manufacturing facilities.

In recent years, China's stringent environmental policies have led to the shutdown of numerous API manufacturers, causing supply shortages and price volatility. For instance, between 2017 and 2018, approximately 145 API manufacturers in China ceased operations due to non-compliance with environmental standards, significantly impacting global API supply chains. Such events underscore the vulnerability of India's pharmaceutical sector, including Bleomycin production, to external supply chain disruptions.

Our proprietary trade data indicates that the top five Indian exporters of Bleomycin account for 47.9% of total exports, with VENUS REMEDIES LIMITED alone contributing 21.7%. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-Aminopenicillanic acid, reducing import dependence. While these initiatives are steps toward self-reliance, their impact on reducing supplier concentration in Bleomycin production remains to be seen.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt maritime transport. Such disruptions can delay the delivery of essential raw materials and finished products, affecting the pharmaceutical supply chain. Additionally, the U.S.-China trade tensions have led to increased scrutiny and potential tariffs on pharmaceutical imports, further complicating supply dynamics.

Regulatory bodies like the FDA and EMA have issued shortage alerts for various drugs due to supply chain disruptions. For example, the FDA's shortage database indicates that 60% of drug shortages in 2025 were linked to just three factories in Asia. While specific data on Bleomycin shortages is limited, the interconnectedness of global supply chains suggests that similar vulnerabilities could affect its availability.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for KSMs and APIs.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical raw materials and intermediates to decrease reliance on imports.

• Strengthen Regulatory Compliance: Ensure adherence to environmental and quality standards to prevent operational disruptions due to regulatory actions.

• Develop Contingency Plans: Establish robust risk management strategies, including alternative shipping routes and inventory buffers, to mitigate potential supply chain disruptions.

• Monitor Geopolitical Developments: Stay informed about international trade policies and geopolitical events that could impact supply chains, allowing for proactive adjustments.

RISK_LEVEL: MEDIUM